ONCODES.PREC.MED. EO-34 Net Assets
ONCODES.PREC.MED. EO-34 net assets. Based on the latest financial reports, ONCODES.PREC.MED. EO-34 (ZR8) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ZR8 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 128.79 |
Net Assets of ONCODES.PREC.MED. EO-34 (2021–2024)
Net assets of ONCODES.PREC.MED. EO-34 from 2021 to 2024. This chart illustrates how ONCODES.PREC.MED. EO-34's net assets have evolved over time, based on quarterly financial data. See ONCODES.PREC.MED. EO-34 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for ONCODES.PREC.MED. EO-34 (2021–2024)
The table below shows the annual net assets of ONCODES.PREC.MED. EO-34 from 2021 to 2024. For live market cap and overall valuation, see ONCODES.PREC.MED. EO-34 (ZR8) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-429.39K ≈ $-502.00K |
-111.63% |
| 2023-12-31 | €3.69 Million ≈ $4.31 Million |
-68.67% |
| 2022-12-31 | €11.78 Million ≈ $13.77 Million |
+180.51% |
| 2021-12-31 | €4.20 Million ≈ $4.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ONCODES.PREC.MED. EO-34's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1258713733.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ONCODES.PREC.MED. EO-34 Net Assets Breakdown (December 2024)
ONCODES.PREC.MED. EO-34 net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €15.10 Million | % |
| Total Equity | €-429.39K | 100.00% |
ONCODES.PREC.MED. EO-34 Competitors by Market Cap
The table below lists competitors of ONCODES.PREC.MED. EO-34 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pulmatrix Inc
NASDAQ:PULM
|
$5.11 Million |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
$5.12 Million |
|
Mantle Minerals Ltd
AU:MTL
|
$5.12 Million |
|
Mint Corp
V:MIT
|
$5.12 Million |
|
Newbury Pharmaceuticals AB
ST:NEWBRY
|
$5.10 Million |
|
Modern Times Group Mtg AB
ST:MTG-A
|
$5.10 Million |
|
Hybrid Financial Services Limited
NSE:HYBRIDFIN
|
$5.10 Million |
|
Fragbite Group AB
ST:FRAG
|
$5.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONCODES.PREC.MED. EO-34's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,690,701 to -429,389, a change of -4,120,089 (-111.6%).
- Net loss of 7,209,619 reduced equity.
- Other factors increased equity by 3,089,530.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.21 Million | -1679.04% |
| Other Changes | €3.09 Million | +719.52% |
| Total Change | €- | -111.63% |
Book Value vs Market Value Analysis
This analysis compares ONCODES.PREC.MED. EO-34's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.61 | €0.23 | x |
| 2022-12-31 | €0.71 | €0.23 | x |
| 2023-12-31 | €0.22 | €0.23 | x |
| 2024-12-31 | €-0.02 | €0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ONCODES.PREC.MED. EO-34 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3482.24%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-72.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -70.10% | -76.86% | 0.46x | 1.99x | €-3.36 Million |
| 2022 | -1.96% | -2.90% | 0.43x | 1.56x | €-1.41 Million |
| 2023 | -219.22% | -754.61% | 0.06x | 4.51x | €-8.46 Million |
| 2024 | 0.00% | -3482.24% | 0.02x | 0.00x | €-7.17 Million |
Industry Comparison
This section compares ONCODES.PREC.MED. EO-34's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONCODES.PREC.MED. EO-34 (ZR8) | €- | -70.10% | N/A | $5.10 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more